(54.237.183.249)
Users online: 2878    [ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2020, Volume : 13, Issue : 6
First page : ( 2733) Last page : ( 2741)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2020.00486.2

Evaluation of New Thiosemcarbazides Derived from Captopril as Angiotensin-Converting Enzyme Inhibitors with Docking Study, and Predicted-ADMET Analysis

Al-Saad Hiba Najeh1, Kubba Ammar A. Razzak Mahmood2,*

1Department of Pharmaceutical Chemistry, College of Pharmacy, Basrah University, Basrah-Iraq

2Department of Pharmaceutical Chemistry, College of Pharmacy-University of Baghdad, Baghdad, 10001-Iraq

*Corresponding Author E-mail: kubbaammar1963@gmail.com

Online published on 4 July, 2020.

Abstract

A series of new captopril thiosemicarbazide derivatives (2–7) were evaluated in vitro for ACE inhibitor activity, using developed colorimetric assay as a simple, sensitive, and cost-effective method. Compounds (4 and 7), substituted with an electron-withdrawing group, showed good ACE inhibition activity, compared to nonsubstituted derivatives, and compounds substituted with electron-donating groups, with percent inhibition of 76.23±0.44 and 79.22±0.25, and IC50 (0.137 and 0.103 μμ), respectively. The molecular docking study revealed good agreement for compounds (4 and 7) with in vitro findings, respectively, with binding energy (−6.99 and -7.3 Kcal/mol). In silico pre-ADMET analysis, all derivatives are supposed to show appropriate intestinal absorption with low BBB penetration, and a closer carcinogenicity score to zero. The lipophilicity of the synthetic compounds, expressed with Clog p values, showed good correlation with in vitro ACE inhibition activity.

Top

Keywords

Captopril, Thiosemicarbazide, ACE, ADMET analysis, and Clog p.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
446,716,535 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.